Renal cell carcinoma

Related records

Broader conditions (19)

• Adenocarcinoma
• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Glandular cell neoplasm
• Human disease
• Kidney cancer
• Kidney disorder
• Kidney neoplasm
• Malignant urinary system neoplasm
• Neoplasm
• Neoplastic disease or syndrome
• Renal carcinoma
• Urinary system disorder
• Urinary system neoplasm

Narrower conditions (36)

• Acquired cystic disease-associated renal cell carcinoma
• Adrenal cortex carcinoma
• Adrenocortical carcinoma, hereditary
• Aniridia 2
• Aniridia 3
• Childhood kidney cell carcinoma
• Childhood renal cell carcinoma with MiT translocations
• Chromophobe renal cell carcinoma
• Classic variant of chromophobe renal cell carcinoma
• Clear cell papillary renal cell carcinoma
• Clear cell renal carcinoma
• Collecting duct carcinoma
• Cystic renal cell carcinoma
• Eosinophilic variant of chromophobe renal cell carcinoma
• Foveal hypoplasia 1
• Hereditary clear cell renal cell carcinoma
• Hereditary papillary renal cell carcinoma
• Hereditary renal cell carcinoma
• Isolated optic nerve hypoplasia
• Kidney medullary carcinoma

Trials (1,985)

• "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
• "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
• [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
• [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
• 177LuPSMA in Renal Cell Carcinoma
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• 18F-FSPG PET/CT for Cancer Patients on Therapy
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
• 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
• 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
• 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement
• 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
• 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
• 68Ga-labeled NY104 PET Imaging in Patients
• 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
• 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
• 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma

Approved drugs (16)

• Axitinib
• Belzutifan
• Bevacizumab
• Cabozantinib S-malate
• Everolimus
• Ipilimumab
• Lenvatinib mesylate
• Medroxyprogesterone acetate
• Nivolumab
• Pazopanib hydrochloride
• Pembrolizumab
• Sorafenib tosylate
• Sunitinib
• Sunitinib malate
• Temsirolimus
• Tivozanib hydrochloride

Drugs in development (196)

• Abexinostat Phase 3
• ABT-510 Phase 2
• ABT-751 Phase 2
• Afeletecan hydrochloride Phase 2
• Aflibercept Phase 2
• Agatolimod sodium Phase 1
• AGS-16C3F Phase 2
• Aldesleukin Phase 3
• Amcasertib Phase 2
• Apitolisib Phase 2
• Archexin Phase 1
• AS-1409 Phase 1
• Atezolizumab Phase 3
• ATN-161 Phase 2
• Atorvastatin Phase 2
• Avelumab Phase 3
• Azacitidine Phase 1
• Balstilimab Phase 2
• Bempegaldesleukin Phase 3
• Bexmarilimab Phase 1

Other linked drugs (10)

• Bicalutamide
• CDX-014
• Coagulation factor X human
• Ieramilimab
• Ketorolac tromethamine
• Mavorixafor
• Pafolacianine
• Sifalimumab
• Tucidinostat
• Zenocutuzumab